Literature DB >> 10348782

Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli.

C Bantar1, F Nicola, H J Arenoso, M Galas, L Soria, D Dana, A Rossi, H Bianchini, A Jasovich.   

Abstract

We evaluated the pharmacokinetics of amoxicillin-sulbactam (AMX-SUL), a novel drug combination, and its pharmacodynamics against Escherichia coli in 12 volunteers receiving a single oral dose (1, 000 mg). Peak serum bactericidal and urine inhibitory activities in most volunteers were observed against E. coli strains for which AMX-SUL MICs were low (2- to 4-mg/liter) (2 strains) and high (>/=16-mg/liter) (47 strains), respectively.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10348782      PMCID： PMC89308          DOI： 10.1128/AAC.43.6.1503

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  ["Beta-lactamase enzymogram": an agar adaptation of the iodometric method (author's transl)].

Authors:  R Labia; M Barthélémy
Journal:  Ann Microbiol (Paris)       Date:  1979-10

2.  Synergy characterization for Enterococcus faecalis strains displaying moderately high-level gentamicin and streptomycin resistance.

Authors:  C E Bantar; M Micucci; L Fernandez Canigia; J Smayevsky; H M Bianchini
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

Review 3.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 4.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

5.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

6.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Authors:  M R Jacobs; S C Aronoff; S Johenning; D M Shlaes; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  Construction by polymerase chain reaction and use of intragenic DNA probes for three main types of transferable beta-lactamases (TEM, SHV, CARB) [corrected].

Authors:  G Arlet; A Philippon
Journal:  FEMS Microbiol Lett       Date:  1991-07-15       Impact factor: 2.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.